NAD+ Injections vs. Precursors: Rethinking Mitochondrial Support

An NAD+ injection can look like the most direct way to support cellular energy.

NAD+ is involved in metabolism, so putting NAD+ directly into the body sounds like an obvious advantage.

But delivery into the bloodstream and delivery into the right cells are different biological questions.

That is why I think injections may be the wrong starting point for many people pursuing general wellness. Oral precursors deserve a closer look—not because they are proven to make everyone healthier, but because several have human evidence for supporting NAD+ production without an injection.

Nicotinamide adenine dinucleotide, or NAD+, helps transfer electrons during energy metabolism. It also participates in processes involving enzymes such as sirtuins and PARPs.

Our bodies continually make, recycle and consume it.

That does not mean more is always better, or that fatigue automatically indicates an NAD+ deficiency. A compound being essential to normal biology does not establish that supplementing it improves health in someone who already has enough.

One terminology point matters here.

Endogenous NAD+ is the NAD+ your body produces. Injected NAD+ is exogenous NAD+—supplied from outside the body.

The injected molecule may be chemically identical to the NAD+ our cells use. The difference is how it reaches the body and how it is processed.

Precursors supply materials that can enter NAD+ synthesis pathways:

These are not interchangeable supplements. Their absorption, metabolism, tolerability and research differ.

The simplified NR-to-NMN-to-NAD+ sequence is useful, but it is not the whole story. Tracer experiments show that oral precursors can be metabolized before reaching tissues, and NAD+ metabolism varies across organs. Much of that detailed tracing evidence comes from animals.

An IV infusion bypasses intestinal absorption. It does not automatically bypass cell membranes, extracellular enzymes or the mechanisms controlling NAD+ inside tissues.

The important question is what happens after administration.

In a small 2019 human study, investigators followed NAD+ and related metabolites during a six-hour IV infusion. Plasma NAD+ did not rise during the first two hours at the studied infusion rate. Later changes in metabolites were consistent with enzymatic processing, and NAD+ itself was also detected in urine.

That does not prove the infusion was useless or that none of it reached tissues.

It shows why “100% delivered into the bloodstream” should not be confused with “100% delivered intact into cells.”

The study examined metabolism, not whether infusions improved longevity, energy or recovery.

It also studied IV administration. Its findings cannot simply be treated as proof for subcutaneous or intramuscular NAD+ injections.

Oral NR can raise NAD+ measures in humans.

A randomized crossover study in middle-aged and older adults found that six weeks of NR increased blood-cell NAD+ measures and was generally well tolerated. It did not establish lifespan extension or broad rejuvenation.

NMN has some encouraging, population-specific findings.

A ten-week randomized trial in postmenopausal women with prediabetes and overweight or obesity found improvements in muscle insulin sensitivity and related signaling. That finding should not be generalized into a claim that NMN treats diabetes or improves metabolism in everyone.

Raising NAD+ does not guarantee symptom improvement.

In a randomized long-COVID trial, NR substantially increased NAD+ levels, but it did not significantly outperform placebo for cognition, fatigue, sleep or mood. The study was small and had substantial dropout, so its precision was limited.

A larger, year-long trial in early Parkinson disease also did not establish benefit: clinical outcomes favored placebo over NR. That is a reminder that a biologically plausible precursor should not be promoted as a treatment for every condition.

My interpretation is that precursors offer a better-studied route for changing NAD+ biology than routine wellness injections. They are not proven clinically superior to injected NAD+ in a robust head-to-head comparison.

Injections introduce considerations that an oral supplement does not: sterile preparation, administration, injection-site complications and, for IV treatment, venous access and infusion tolerability.

A 2026 retrospective study from a commercial infusion setting reported gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ infusions. It was not a randomized efficacy trial, and it compared IV NAD+ with IV NR—not oral NR.

Product quality is another issue.

FDA has warned about food-grade NAD+ ingredients being used to prepare sterile injectables. It received reports of severe chills, shaking, vomiting and fatigue consistent with excessive endotoxin exposure. Those reports concern preparation quality; they do not establish that all NAD+ products cause those reactions.

The point is to ask whether the additional procedure and product-quality demands come with a demonstrated benefit for the intended goal.

For general wellness, that benefit has not been established by the infusion studies discussed here.

This is where I would be careful with the word necessary.

Current evidence does not establish a routine requirement for NAD+ injections to treat ordinary fatigue, support healthy aging or maintain NAD+ levels in otherwise healthy people.

A specialist might investigate parenteral NAD+ within a research protocol or consider an individualized use. That is different from an established indication showing that a patient needs injected NAD+ rather than another treatment.

There are genuine situations in which NAD-related nutrition matters.

Severe niacin deficiency causes pellagra and requires appropriate vitamin replacement. That is not automatically a reason to inject NAD+. People unable to maintain adequate oral nutrition need medical assessment and an appropriate nutrition plan.

A small study in a specific mitochondrial myopathy population identified NAD+ deficiency and reported improvements with niacin treatment. The intervention was a vitamin B3 precursor—not an NAD+ injection—and it does not establish a general treatment for fatigue or mitochondrial dysfunction.

So I would not present severe depletion, poor oral tolerance or malabsorption as automatic proof that an NAD+ injection is required. The diagnosis and the evidence for the specific treatment still matter.

NAD+ availability is only one part of mitochondrial health. Electron transport, antioxidant defenses and mitochondrial protein production also matter. That is where supplements such as CoQ10, PQQ, glycine and taurine enter the discussion.

CoQ10: An electron carrier in the mitochondrial respiratory chain, helping move electrons through the machinery used to produce ATP. Its biological role is well established, but supplementation is most meaningful in specific contexts, including CoQ10 deficiency. That does not guarantee an energy boost in someone with adequate levels.

PQQ: Studied for effects on signaling associated with mitochondrial biogenesis—the production of new mitochondria. A small human exercise trial found an increase in the signaling protein PGC-1α, but no additional improvement in aerobic performance. A change in a marker is not proof of better mitochondrial function or endurance.

Glycine: One of the building blocks of glutathione, an important cellular antioxidant. Small human trials of glycine combined with N-acetylcysteine, known as GlyNAC, have reported improvements in glutathione status and measures of mitochondrial fuel oxidation in older adults. Those results apply to the combination, not proof that glycine alone produces the same effects.

Taurine: Participates in modifications to mitochondrial transfer RNA that help mitochondria make proteins correctly. Clinical research in the rare mitochondrial disorder MELAS supports a disease-specific role, but it does not establish that taurine supplements improve energy or longevity in healthy adults.

These compounds are not direct NAD+ precursors. They relate to different parts of mitochondrial biology, and their evidence should be evaluated separately. Supporting mitochondria is a broader discussion than simply increasing one molecule.

I think the strongest argument is about choosing a sensible starting point.

If someone is considering NAD support, an oral precursor may offer a more practical approach: no injection procedure and a stronger human research base for increasing NAD+ measures.

But that is a reason for a discussion—not a reason for everyone to start supplementing.

Niacin and nicotinamide can cause adverse effects at high supplemental doses, and evidence for long-term NR or NMN benefits remains incomplete. Ingredient identity, product quality, medical conditions and medications all matter.

The question is not simply whether we can raise NAD+. It is whether doing so improves an outcome that matters, in the person using it, with an acceptable tradeoff.

For many people pursuing general wellness, jumping straight to NAD+ injections gets ahead of the evidence. Precursors may deserve consideration first, while recognizing that neither approach is a universal solution.

— Beardedmuscle

View the supplements in my TikTok showcase (opens in a new tab)

Educational discussion, not individualized treatment advice.